PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Negative EBIT growth while TRAW is at 24.88%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-35.03%
Negative operating income growth while TRAW is at 24.88%. Joel Greenblatt would press for urgent turnaround measures.
-37.55%
Negative net income growth while TRAW stands at 26.41%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-34.88%
Negative EPS growth while TRAW is at 28.57%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-34.88%
Negative diluted EPS growth while TRAW is at 28.57%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.03%
Share count expansion well above TRAW's 0.09%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.03%
Diluted share count expanding well above TRAW's 0.09%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.51%
OCF growth above 1.5x TRAW's 1.17%. David Dodd would confirm a clear edge in underlying cash generation.
9.65%
FCF growth above 1.5x TRAW's 1.17%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
10Y OCF/share CAGR at 50-75% of TRAW's 99.99%. Martin Whitman might fear a structural deficiency in operational efficiency.
54.54%
5Y OCF/share CAGR at 50-75% of TRAW's 98.74%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-31.27%
Negative 3Y OCF/share CAGR while TRAW stands at 55.04%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
85.15%
Net income/share CAGR at 75-90% of TRAW's 99.99%. Bill Ackman would press for strategic moves to boost long-term earnings.
56.20%
5Y net income/share CAGR at 50-75% of TRAW's 98.77%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-42.46%
Negative 3Y CAGR while TRAW is 69.04%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-24.53%
Negative equity/share CAGR over 10 years while TRAW stands at 100.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-54.63%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.07%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.00%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
41.18%
We increase R&D while TRAW cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
22.12%
SG&A growth well above TRAW's 4.64%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.